Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish
  • Turkish

Breadcrumb

  1. Home
  2. Gynecology
  3. Using recombinant endolysins to treat bacterial vaginosis
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gynecology
  3. Using recombinant endolysins to treat bacterial vaginosis
Gynecology

Using recombinant endolysins to treat bacterial vaginosis

Vaginosis
Gynecology

A study has shown that by using recombinant endolysins encoded on a prophage it is possible to eliminate the bacterial biofilm responsible for bacterial vaginosis without damaging the beneficial bacteria of the vaginal microbiota. These are promising results.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 21 April 2021
Updated 06 October 2021

Bacterial vaginosis is a quite common disorder in women of reproductive age, with a prevalence estimated at 10%–30% worldwide. It is associated with an increased risk of infertility and complications during pregnancy. It is also a risk factor for contracting sexually transmitted diseases. The condition is characterized by an imbalance of the vaginal microbiota and a biofilm formed on the vaginal epithelium, which is initiated and dominated by Gardnerella bacteria. This biofilm is frequently refractory to antibiotic treatment. Antibiotics are effective in quickly reducing symptoms but are associated with a recurrence rate of up to 60% within six months of treatment. A new study has investigated (sidenote: Endolysins Bacteriophage enzymes that lyse the bacterial wall, allowing the release of phages. )  of the type 1,4-beta-N-acetylmuramidase encoded on Gardnerella (sidenote: Prophages Bacteriophage genomes integrated into the host genome. (Saussereau and Debarbieux 2012) )  as an alternative treatment.

Bactericidal effect 10 times higher than wild type

To this end, the authors generated several engineered endolysins via domain shuffling. They compared their bactericidal activity on Gardnerella strains to that of wild-type endolysins. The bactericidal activity of the recombinant endolysins was 10 times that of any wild-type enzyme. When tested against a panel of 20 Gardnerella strains (from (sidenote: G. vaginalis, G. leopoldii, G. piotii and G. swidsinskii ) ), the most active endolysin, called PM-477, showed superior efficacy compared to the antibiotics tested (metronidazole, tinidazole, clindamycin). Furthermore, PM-477 had no effect on beneficial lactobacilli or other species of vaginal bacteria. According to the authors, PM-477 is highly selective for Gardnerella and kills strains of each of the four main species without affecting beneficial lactobacilli or other species typical of the vaginal microbiota. The effect of PM-477 was confirmed by microscopy in mixed cultures of Gardnerella and lactobacilli. PM-477 (at 460 µg/mL for 5 h) lysed G. vaginalis and G. swidsinskii cells in monoculture, but also selectively lysed them in mixed cultures alongside lactobacilli without affecting the latter.

Efficacy in patient samples

To go further and analyze the efficacy of PM-477 in a physiological environment closely resembling the in vivo situation, the researchers treated vaginal swabs from 15 bacterial vaginosis patients and analyzed them by fluorescence in situ hybridization (FISH). They showed that in 13 of the 15 cases, PM-477 eradicated the Gardnerella bacterium and physically dissolved the biofilms without affecting the vaginal microbiota. For the authors, endolysins are a promising therapeutic alternative to antibiotics for the treatment of bacterial vaginosis. This is a significant finding since antibiotics are frequently a cause of recurrence and resistance in the treatment of the disease.

Sources

Landlinger C, Tisakova L, Oberbauer V, Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo. Pathogens. 2021 Jan 8;10(1):54.

Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res. 2012;83:123-141. 

Tags
Vaginosis Gardnerella vaginalis Lactobacilli

en_view en_sources

    Created 21 April 2021
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Vaginosis

    Medical practice

    Gynecology

    Content type

    News
    Gynecology

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Vaginal Microbiota # 16

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Vaginal microbiota # 14

    By Pr. Markku VoutilainenTurku University Faculty of Medicine; Turku University Hospital, Department of Gas...

    Find out more

    Vaginal Microbiota #15

    By Pr. Markku VoutilainenTurku University Faculty of Medicine; Turku University Hospital, Department of Gas...

    Find out more

    Urinary tract infections

    Infections of the lower urogenital tract are extremely common amongst women: seven out of ten women will su...

    Find out more

    Vaginal microbiota #10

    By Pr. Markku VoutilainenTurku University Faculty of Medicine; Turku University Hospital, Department of Gas...

    Find out more

    Targeting the gut microbiota to optimize vaccine efficacy?

    by Dr Genelle Healey

    Find out more

    The hygiene hypothesis and the COVID-19 pandemic

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Cancer du col de l’utérus : l’étau se resserre sur L. iners
    14.02.2023

    Cervical cancer: the walls are closing in on L. iners

    Read the article
    Pregnancy: is vaginal dysbiosis responsible for complications in case of COVID-19?
    06.01.2023

    Pregnancy: is vaginal dysbiosis responsible for complications in case of COVID-19?

    Read the article
    Photo: WAAW 2022 (HCPs)
    25.10.2022

    Microbiota at the forefront of antibiotic resistance

    Read the article
    25.10.2022

    Antibiotics: Dr Jekyll and Mr Hyde

    Read the article
    Everything you need to know about Microbiota & Dysbiosis
    27.07.2022

    Everything you need to know about Dysbiosis

    Read the article
    Photo: Antibiotic resistance is a web of several problems (HCPs)
    02.11.2022

    Antibiotic resistance is a web of several problems

    Read the article
    Actu PRO : Une antibiothérapie prophylactique péri-partum appauvrit le lait maternel en Bifidobacterium
    12.03.2019

    Peripartum prophylactic antibiotic therapy decreases bifidobacterium levels in breast milk

    Read the article
    28.10.2021

    6 things you should know about antibiotics

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish
    • Turkish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo